Wallace Group is proud to be a part of the team helping bring Serán BioScience's new commercial manufacturing facility to life in Bend. It's exciting to see the project reach another major milestone with the building now fully enclosed. Developments like this support the continued growth of Central Oregon's life sciences industry and will help expand commercial manufacturing capabilities for years to come. Congratulations to Serán BioScience, Mortenson, and the entire project team—we're grateful for the opportunity to contribute and look forward to seeing the facility completed!

Exciting to see Serán BioScience vision becoming reality. Proud of Mortenson’s partnership in delivering a world-class facility that will help bring life-changing therapies to market faster.

𝗧𝗵𝗲 𝗚𝗟𝗣-𝟭 𝗯𝗼𝗼𝗺 𝗶𝘀 𝗿𝗲𝘄𝗿𝗶𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝘂𝗹𝗲𝘀 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆. As demand for GLP-1 therapies accelerates, the autoinjector supply chain faces unprecedented pressure, from fill-finish capacity to device assembly constraints. Pharma companies are rethinking strategies, embracing platform-based solutions, and prioritizing flexibility to keep pace. At Ensera, we’re helping clients navigate this complexity with flexible final assembly and secondary packing services, expanding cleanroom and cold-chain capacity, and a commitment to supporting small-to-mid-volume programs clinical trials, and orphan drugs. Discover the trends shaping the future of drug-device combination products and why agility matters more than ever. Read the full article: The impact of GLP-1 demand on the autoinjector supply Chain https://lnkd.in/dKw88kQW

Breaking News‼️‼️ Endpoints News is hosting Manufacturing Day on August 5th, a full half-day dedicated to how biopharma is navigating tariff disruptions and the manufacturing trends coming next. The fact that this event exists tells you everything. A year ago, pharma manufacturing was background infrastructure. Nobody talked about it publicly. Now it's front-page news, a national security conversation, and the subject of a dedicated industry event. We have been building Mustard Biopharma for this moment, not because of the tariffs, but because the fragility they exposed was always there. Mustard Biopharma AI-native, software-defined dark factories. Anti-cancer medicines produced 10x faster, 30x cheaper than the current CDMO model. If you're attending Manufacturing Day, I'd love to connect. #PharmaManufacturing #Biopharma #MustardBiopharma #FactoryOS #PharmaReshoring

The pressure to accelerate drug development has never been greater. But speed alone isn't enough—every decision made during scale-up must be backed by deeper process understanding and robust data. In a recent interview with Brian K. Buntz, Editor-in-Chief of Drug Discovery & Development, Tuneer Ghosh, President – CMC, shares how Sai Life Sciences is taking an information-dense approach to scale-up—combining process science, digital technologies and cross-functional collaboration to help pharma innovators compress timelines while reducing development risk. Read the full article here: https://lnkd.in/gV6evb7M #Sailifesciences #cmc #drugdevelopment #scaleup #speed #pharma #cdmo #crdmo #drugdiscovery

🚀 What does it take to keep a clinical programme flexible when launch plans can change overnight? Reflecting on Outlook Therapeutics' European launch journey, Jedd Comiskey, SVP – Head of Europe, explains how flexibility, coordination and the right operating model helped the organisation navigate a highly complex environment. 💡 His experience reinforces one of the key themes explored in our latest article: as clinical studies become increasingly global and operationally complex, organisations need sourcing and operational strategies that can adapt quickly as circumstances evolve. #Alcura #ClinicalTrials #ClinicalOperations #Biotech #Pharma #LifeSciences #ClinicalDevelopment #Commercialization #HealthcareInnovation #SupplyChain

Improving solubility is a critical challenge in oral drug development. With spray drying, you can turn poorly soluble compounds into amorphous solid dispersions—enhancing bioavailability and accelerating your path to clinic. In this video, learn from our colleague Craig Sather how to decide whether spray drying is the right approach for your molecule, and how to make more informed formulation decisions early on. At Lonza, we combine deep expertise with integrated development and manufacturing to help you reduce risk and move forward with confidence. 👉 Connect with our experts to learn more: https://ow.ly/gbO230sX7J9 #SprayDrying #Bioavailability #SmallMolecules #DrugDevelopment #CDMO #Lonza

What does rising GLP-1 demand mean for sterile injectable manufacturing? In The Medicine Maker’s latest Biopharma Vital Signs article, Mike Ford, Director of Sales and Business Development at Kindeva, shares why growing demand is making sterile injectable manufacturing more complex, and why development, fill finish and supply planning need to be considered together. The article brings together industry perspectives on the trends reshaping biotech and biopharma development, from manufacturing pressures and funding constraints to commercialization planning. See what they had to say: https://loom.ly/EP7oJKk #SterileInjectables #GLP1 #PharmaManufacturing

Bringing innovative therapies to patients requires more than great science, it takes the right development and manufacturing strategy! One area that's generating a lot of interest is scalable powder-in-capsule development. With Catalent's Astrapi platform, programs can move seamlessly from early clinical development through commercial manufacturing, helping reduce technology transfers while supporting speed, flexibility, and cost efficiency. If you're evaluating options for your next oral solid dose program, I'd be happy to discuss how Catalent can help accelerate your path to the clinic. #DrugDevelopment #Pharma #CDMO #OralSolidDose #ClinicalTrials #Catalent

Big Pharma isn't buying drugs. It's buying time. Biopharma dealmaking hit $106B across 201 deals so far in 2026 — driven by looming patent cliffs and Big Pharma's race to rebuild pipelines (PitchBook data via CNBC, linked below). With $200B+ in branded revenue losing exclusivity by 2030, acquirers aren't shopping for science. They're shopping for durable IP, de-risked assets, and portfolio fit. Context from CNBC: https://lnkd.in/g6zNmceW #Biotech #PharmaMA #PatentCliff #IntellectualProperty #LifeSciences #VentureCapital #BiotechInvesting #DrugDevelopment Colorado BioScience Association Whiteford, Taylor & Preston LLP